DIRS.INFO The most relevant business & tech news

☆ Covid Shots May Slightly Raise Stroke Risk in the Oldest Recipients
▼ + stars: | 2023-10-24 | by ( Apoorva Mandavilli | More About Apoorva Mandavilli | ) www.nytimes.com time to read: +1 min

The Covid vaccines made by Pfizer-BioNTech and Moderna may be linked to a slight increase in the risk of stroke when administered along with a high-dose flu vaccine, according to a new analysis by the Food and Drug Administration. The high-dose flu vaccine is usually given to older people, and the risk association is clearest in adults aged 85 and older. But that increase, if real, seems very small, and it is possible that the risk may stem from the flu vaccine alone. A separate analysis by the agency points to a small increase in the incidence of seizures after Covid vaccinations in children ages 2 to 5. Flu and Covid themselves both raise the risk of stroke.

Organizations: Pfizer, BioNTech, Food and Drug Administration

☆ Lightning Round: T-Mobile is the best buy in the telecom group, says Jim Cramer
▼ + stars: | 2023-10-24 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: T-Mobile is the best buy in the telecom group, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stocks including: Moderna, Planet Fitness, MGM Resorts, AT&T and more.

Persons: Jim Cramer Organizations: Mobile, Moderna, MGM Resorts

☆ Cramer's Lightning Round: AT&T is 'not my favorite'
▼ + stars: | 2023-10-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Moderna's year-to-date stock performance. Stock Chart Icon Stock chart icon Planet Fitness's year-to-date stock performance. Stock Chart Icon Stock chart icon AT&T's year-to-date stock performance. Stock Chart Icon Stock chart icon Leonardo DRS's year-to-date stock performance. Stock Chart Icon Stock chart icon Marathon Digital's year-to-date stock performance.

Persons: they've, I'm, Wynn, Leonardo DRS's, Leonardo DRS Organizations: MGM Resorts, Mobile

☆ Nike is among the most overbought stocks in the S&P 500. Here are the others
▼ + stars: | 2023-10-20 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

A stock with a 14-day RSI greater than 70 is considered to be overbought and at risk of a pullback. Here are some of the most overbought names: Sports apparel retailer Nike has a 14-day RSI of 81.89, and just under half of analysts covering the stock rate it a buy. Lockheed Martin is another one of the most overbought companies in the S & P 500. The U.S. defense contractor scored a 14-day RSI of 77.69, with a consensus price target implying 6.8% upside. Also on the oversold list is pharmaceutical company Moderna , which has a 14-day RSI reading of 15.5.

Persons: Piper Sandler, Lockheed Martin, Invesco, Jason Haas, Haas, — CNBC's Michael Bloom Organizations: Nike, Dow Jones, CNBC Pro, Insurance, Cardinal Health, Allstate, Humana, Investment, Hasbro, Wall, Bank of America, Monopoly, Moderna, Pfizer, FedEx Locations: U.S, Lowe's

☆ Japan agreed to buy additional COVID-19 vaccine doses from Pfizer and Moderna
▼ + stars: | 2023-10-19 | by ( ) www.reuters.com time to read: 1 min

World category · October 24, 2023 · 1:14 AM UTCChina will do its utmost when it comes to contributing to Palestinian-Israeli reconciliation, its foreign minister told his Israeli counterpart in a phone call on Monday, according to Chinese state media.

Locations: China, Palestinian

☆ Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
▼ + stars: | 2023-10-19 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsLONDON, Oct 19 (Reuters) - Eli Lilly (LLY.N) has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday. Lilly has said it expects U.S. approval for Mounjaro for weight loss by the end of the year. The source told Reuters that CordenPharma's factory in Colorado is under contract to make tirzepatide, the active ingredient in the weekly injection. Analysts estimate the obesity market could be worth as much as $100 billion in the next decade.

Persons: Eli Lilly, Mike Segar, drugmaker, CordenPharma, Lilly, Corden, Maggie Fick, Josephine Mason, Bill Berkrot Organizations: Company, REUTERS, Reuters, CordenPharma, Novo Nordisk, Mounjaro, Thomson Locations: Branchburg , New Jersey, Switzerland, United States, Colorado, Basel, Europe, Boulder , Colorado, Boulder

Consumer discretionary (.SPLRCD) and materials (.SPLRCM) led the gains across major S&P 500 sectors, while utilities (.SPLRCU) and energy stocks (.SPNY) lagged behind. Third-quarter earnings for S&P 500 companies are estimated to grow 2.2% year-on-year, LSEG data showed on Friday. Investors also await economic data including retail sales for September and the Philly Fed Business Index for October later this week. Lululemon Athletica (LULU.O) added 9.6% as the sportswear apparel maker is set to join the S&P 500 index this week, replacing Activision Blizzard . The S&P index recorded nine new 52-week highs and six new lows, while the Nasdaq recorded 29 new highs and 148 new lows.

Persons: Brendan McDermid, Charles Schwab, Dow, Ross Mayfield, Baird, Goldman Sachs, Morgan Stanley, Johnson, Jerome Powell's, Patrick Harker, Lululemon, Ankika Biswas, Shashwat Chauhan, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Moderna, Dow, Nasdaq, Microsoft, Bank of America, Johnson, Tesla, Netflix, Investors, Philly, Dow Jones, Federal, Fed, Philadelphia Fed, Apple, Activision Blizzard, NYSE, Thomson Locations: New York City, U.S, Israel, Gaza, New York State, China, Bengaluru

☆ Pfizer, BioNTech shares fall on lower COVID product sales forecast
▼ + stars: | 2023-10-16 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/File photo Acquire Licensing RightsOct 16 (Reuters) - Shares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations. The COVID sales forecast cut was bigger than expected, Wells Fargo analyst Mohit Bansal said, adding that Wall Street's COVID sales estimates for the next few years may come down. Shares in BioNTech, which is also developing cancer treatments, were down 6.7% at a two-month low in Frankfurt. Its U.S.-listed shares fell 6.8% in premarket trading, while Pfizer's shares fell 2%. The news also dragged down shares of rival COVID vaccine maker Moderna (MRNA.O) by 4.7%.

Persons: Dado, BioNTech, drugmaker, Wells, Mohit Bansal, Ludwig Burger, Rachel More, Miranda Murray, Jason Neely, Shounak Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, U.S, Its U.S, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Wells Fargo, BioNTech, Frankfurt, Its, Bengaluru

Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., September 28, 2023. The S&P 500 and the Nasdaq dropped on Friday as deteriorating consumer sentiment data and the Middle East conflict kept investors away from riskier bets and overshadowed some upbeat earnings from big U.S. banks. Third-quarter earnings for the S&P 500 companies are estimated to grow 2.2% on an annual basis, LSEG data showed. Of the 32 S&P 500 companies that have reported results, 87.5% have surpassed expectations compared with the long-term average of 66.5%. Rival Moderna (MRNA.O) dipped 5.1%Lululemon Athletica (LULU.O) added 5.8% as the sportswear apparel maker is set to join the S&P 500 index this week, replacing Activision Blizzard (ATVI.O).

Persons: Brendan McDermid, Antony Blinken, Pissouros, Goldman Sachs, Morgan Stanley, Johnson, Charles Schwab, Patrick Harker, Jerome Powell, Harker, Austan Goolsbee, Ankika Biswas, Shashwat Chauhan, Arun Koyyur, Vinay Dwivedi Organizations: New York Stock Exchange, REUTERS, Reuters, Pfizer, Dow, Nasdaq, Treasury, XM, Bank of America, Johnson, Tesla, Netflix, Philly, New York, Philadelphia Fed, Federal, Chicago Fed, Dow e, Nvidia, Activision Blizzard, Thomson Locations: New York City, U.S, China, Israel, Gaza, United States, Bengaluru

Vaccine makers are depending on the U.S. market as many countries have more limited yearly campaigns for giving updated shots. For BioNTech, Moderna, and Novavax (NVAX.O), COVID vaccines remain their only approved products. Shares of Pfizer were up nearly 5%, however, buoyed by a $3.5 billion cost-cutting plan the drugmaker announced late on Friday alongside its new COVID sales outlook. Moderna, in a statement on Monday, maintained its current revenue forecast of $6 billion to $8 billion for its COVID vaccine for 2023. Jefferies analyst Michael Yee said Pfizer's new COVID outlook implies lower vaccine sales for Moderna than it had forecast.

Persons: Dado, BioNTech, Albert Bourla, Bourla, Mani Foroohar, Foroohar, Jefferies, Michael Yee, Ludwig Burger, Rachel More, Michael Erman, Bhanvi Satija, Manas, Jonathan Oatis, Caroline Humer, Bill Berkrot Organizations: COVID, Institute for Health, Food, REUTERS, Pfizer, Moderna, Manas Mishra, Thomson Locations: Zenica, Bosnia, Herzegovina, Frankfurt, Novavax, U.S, New York, Bengaluru

☆ Stocks making the biggest moves midday: Lululemon, Pfizer, News Corp, Charles Schwab and more
▼ + stars: | 2023-10-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Pfizer — Shares rallied 3.61% following an upgrade by Jeffries to buy from hold. The firm sees an attractive buying opportunity after Pfizer cut its full-year guidance last week on slumping vaccine sales. Alignment Healthcare — Shares soared 17.22% after being upgraded to strong buy from outperform by Raymond James. Tal Education — The education technology stock popped 6.73% after UBS upgraded shares to a buy rating, citing an attractive valuation and tailwinds from Tal Education's nonacademic tutoring business. Greenbrier — Shares of the transportation services company gained 3.81% Monday morning after Susquehanna upgraded the stock to a positive rating.

Persons: Dow, Lululemon, Jeffries, Novavax, Raymond James, Morgan Stanley, Jim Ratcliffe, Sheikh Jassim bin Hamad al Thani, Glazer, Tal Education's, Charles Schwab —, Schwab, Albemarle —, Albemarle, Bascome, Henry Schein —, Yun Li, Fred Imbert, Hakyung Kim, Samantha Subin, Alex Harring, Pia Singh, Lisa Han Organizations: Dow Jones Indices, Activision, Microsoft, Pfizer —, Pfizer, Moderna, News Corp, Reuters, Street, Street Journal, Systems, Manchester United, Tal Education, UBS, Liontown, Greenbrier —, Susquehanna Locations: BioNTech, Greenbrier

☆ Stocks making the biggest moves premarket: Pfizer, Lululemon, Manchester United, Rite Aid and more
▼ + stars: | 2023-10-16 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Pfizer , Moderna , BioNTech — Shares of Pfizer dropped 1.3% after the company slashed its full-year revenue guidance by $9 billion, noting waning demand for its Covid treatment and vaccine. Following the guidance cut, Jefferies upgraded Pfizer on Monday, citing an attractive buying opportunity. Vaccine markers Moderna and BioNTech also dropped premarket, losing 4.1% and 5%, respectively. Colgate-Palmolive — The consumer products stock gained more than 1% in premarket trading after Stifel upgraded Colgate-Palmolive to buy from hold. The firm cited the stock's attractive valuation and the rapid and profitable growth of TAL's non-academic tutoring business as catalysts.

Persons: Jefferies, BioNTech, premarket, Morgan Stanley, Jim Ratcliffe, Jeffrey Stein, Dow, Charles Schwab, CNBC's Hakyung Kim, Jesse Pound, Tanaya Macheel, Michelle Fox Theobald, Lisa Han Organizations: Pfizer, Moderna, BioNTech, Colgate, Palmolive, Manchester United, Wall Street, . Rite, Dow Jones, Activision, Microsoft, TAL Education Group, UBS Locations: New Jersey

☆ Moderna reaffirms annual COVID vaccine sales forecast
▼ + stars: | 2023-10-16 | by ( ) www.reuters.com time to read: 1 min

Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing RightsCompanies Moderna Inc FollowPfizer Inc FollowOct 16 (Reuters) - Moderna (MRNA.O) on Monday reaffirmed its forecast of $6 billion to $8 billion in COVID vaccine sales for the year, after rival Pfizer (PFE.N) slashed forecast for its vaccine last week. Moderna said it will have "improved visibility" about the expected U.S. market size for vaccines after observing trends through October 2023. Shares of Moderna were down about 4% in premarket trading. Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Dado Ruvic, Bhanvi, Shilpi Majumdar Organizations: REUTERS, Moderna Inc, Pfizer, Moderna, Thomson Locations: Bengaluru

☆ Over 7 million Americans have gotten updated COVID vaccines
▼ + stars: | 2023-10-12 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

Millions of doses of another updated COVID vaccine from Novavax (NVAX.O) have also been made available to Americans this week, according to the company. Last year's booster targeting the original virus and another variant was rolled out about 10 days earlier. By Sept. 28, 2022, almost 7.6 million Americans had received the updated shots. U.S. public health officials have been optimistic that Americans will get the new vaccines and have recommended that everyone ages 6 months and older receive one. About 17% of the U.S. population, or 56.5 million people, ultimately received last year's version of the vaccines.

Persons: Emily Elconin, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, U.S . Department of Health, Human Services, Pfizer, Moderna, U.S . Centers, Disease Control, Thomson Locations: Waterford , Michigan, U.S, Moderna, Novavax

☆ Analysts say these stocks have the most upside from here — including one solar name expected to double
▼ + stars: | 2023-10-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Wall Street is trying to shake off a myriad of headwinds, and analysts see certain stocks rallying from here. JPMorgan said in September that the stock is attractive for the long term, as survey data shows growing interest in residential solar panels. "We believe the survey results signal that homeowner interest for adding residential solar systems is stronger than currently low investor sentiment and recent under performance of residential solar stocks indicates," the bank said. SEDG YTD mountain SolarEdge stock. Discovery also made the list, with the average analyst price target calling for more than 76% upside.

Persons: Dow Jones, SolarEdge, JPMorgan, — CNBC's Michael Bloom Organizations: Dow, CNBC Pro, Barclays, Warner Bros, Moderna Locations: Israel

The two Africa-based vaccine manufacturers are receiving $5 million each in funding from the foundation, while another $10 million is earmarked for other companies that have not yet been named. Political Cartoons View All 1202 ImagesThe mRNA vaccine technology came to the forefront with the production of COVID-19 vaccines made by Pfizer and Moderna. Those COVID-19 mRNA vaccines were fast-tracked through the regulatory process and granted emergency use authorization. The new vaccines under development in Africa face a far longer development timeline — anywhere from three to seven years. It has spent billions of dollars to vaccinate against polio, treat and prevent malaria and HIV and more recently advance vaccines for diseases like cholera.

Persons: Melinda Gates, Bill Gates, “, Dr, Amadou Sall, ” Sall, COVID, ” Jose Castillo, ___ Mark Carlson Organizations: Melinda Gates Foundation, Associated Press, Institut Pasteur, Quantoom Biosciences, Pfizer, Moderna, Gates Foundation Locations: DAKAR, Senegal, Africa, Dakar, South Africa, Belgium, Crimean, Congo, Nivelles

☆ Nobel Prize winner Katalin Karikó raised a two-time Olympic gold medalist: Here's her No. 1 piece of parenting advice
▼ + stars: | 2023-10-08 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +1 min

On Monday, Katalin Karikó won the Nobel Prize in Physiology and Medicine. Her research with Drew Weissman, with whom she shares the prize, laid the foundation for the Covid-19 vaccines developed by BioNTech-Pfizer and Moderna. During her time at the University of Pennsylvania she had trouble securing grant funding and bounced from lab to lab. "When I was doing the research I could see the promise," she tells CNBC Make It. She holds an undergraduate and masters degree from the University of Pennsylvania and an MBA from the University of California, Los Angeles.

Persons: Katalin Karikó, Drew Weissman, Susan Francia Organizations: Medicine, BioNTech, Pfizer, Moderna, Karikó's, University of Pennsylvania, CNBC, University of California Locations: Los Angeles

The U.S. government in May ended the COVID public health emergency declaration during which it bought the shots and provided them to all Americans for free. In the current privatized system, health insurance plans by law must cover the shots at no cost. McKesson (MCK.N), one of the largest U.S. wholesalers, said it has distributed over 3.8 million shots so far. "Health insurance providers continue to educate Americans about where and how to get their COVID vaccines within their plan’s coverage," David Allen, a spokesperson for insurance lobby group AHIP said. Now that the government is no longer footing the bill for their vaccine supply, pharmacy owners need to pay for the shots.

Persons: Kate MacDowell, MacDowell, Kaiser, David Allen, AHIP, David Kohll, James Daily, he's, Suzanne Berman, Michael Erman, Ahmed Aboulenein, Caroline Humer, Bill Berkrot Organizations: Pfizer, U.S . Department of Health, Human Services, Kaiser Permanente, COVID, Moderna, CVS, Walmart, Walgreens, Walgreens Boots Alliance, Cardinal Health, Reuters, Kohll's Pharmacy, Thomson Locations: WASHINGTON, U.S, Portland , Oregon, Oregon, California, Nebraska, Readington , New Jersey, Crossville , Tennessee, New York, Washington

☆ Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
▼ + stars: | 2023-10-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

The biotech company is banking on sales of its updated Covid vaccine — its only commercially available product — and a broad cost-cutting push to help it stay afloat. Novavax's shot fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles. The federal government shifted Covid vaccine distribution and coverage to the private market for the first time this fall. A sign advertises COVID-19 (coronavirus) vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, August 14, 2023. Some pharmacies, like Walgreens , also appear to be resolving supply disruptions, which left many stores without any new Covid shots for patients to receive.

Persons: Patrick Van Katwijk, Novavax, aren't, Mayank Mamtani, fends, Silvia Taylor, Taylor, Novavax's, Mamtani, Hannah Beier, Jefferies, Roger Song, Brian Snyder, Biden Organizations: Dutch Health Service Organization, Getty, Pfizer, Moderna, Drug Administration, Riley Securities, CNBC, Covid, FDA, Bloomberg, Insurance, Walgreens, Reuters Locations: The Hague, Netherlands, U.S, Schwenksville , Pennsylvania, Somerville , Massachusetts

☆ Nobel Prize winner Katalin Karikó was 'demoted 4 times' at her old job. How she persisted: 'You have to focus on what's next'
▼ + stars: | 2023-10-06 | by ( Aditi Shrikant | ) www.cnbc.com time to read: +6 min

On Monday, Karikó, along with her collaborator Drew Weissman, won the Nobel Prize in Physiology and Medicine. It's clear, and impressive, that Karikó didn't take those obstacles personally. Suhadolnik didn't receive the news well, she says. If you have a Ph.D. from an American Ivy League [university], that's better compared to if you have a degree from a foreign university." The type of work Karikó does, Feigl-Ding says, doesn't make splashy headlines, because groundbreaking work rarely does.

Persons: Pfizer Covid, Katalin, Drew Weissman, Karikó, didn't, Robert J, Suhadolnik, Susan, Suhadolnik didn't, Gregory Zuckerman's, I'm, wasn't, Eric Feigl, Ding, doesn't, Nobel, Albert Einstein didn't, Ding epidemiologist, Weissman Organizations: Pfizer, Moderna, CNBC, University of Pennsylvania, University of Szeged, Biological Research, Temple University, Uniformed Services University of, Health Sciences, New, Systems Institute, Harvard Medical School, American Ivy League, Universities, Systems, Harvard Medical Locations: Hungary, Philadelphia, Bethesda , Maryland, UPenn, United States, U.S, New England

☆ Moderna combination Covid, flu vaccine moves to final stage trial after positive data
▼ + stars: | 2023-10-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Wednesday said its combination vaccine targeting Covid and the flu will move to a final stage trial in adults ages 50 and above this year after showing positive results in an early to mid-stage study. The trial evaluated the combination shot in two different age groups: people 50 to 64 years of age and participants 65 to 79. The safety data of mRNA-1083 was similar to that of the stand-alone Covid shot, according to Moderna. No new safety concerns were identified with the combination vaccine. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV.

Persons: Stéphane Bancel, BioNTech Organizations: Moderna, Pfizer, GlaxoSmithKline Locations: Moderna

☆ Stocks making the biggest moves premarket: Cal-Maine Foods, Intel, Apple & more
▼ + stars: | 2023-10-04 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Intel — Shares popped 2.5% after the chipmaker announced it would be operating its programmable chip unit as a standalone business complete. Intel plans to conduct an initial public offering for the unit within the next two to three years. The firm is bullish on the stock thanks to progress on legacy projects and said Fluor is on the brink of a company turning point. Sunrun , Sunnova Energy International — Shares of Sunrun and Sunnova dropped 3% and 2.8%, respectively, after Truist Securities downgraded the solar panel installers to hold from buy on Wednesday. Cal-Maine Foods — The stock plunged 11.6% after the company came out with disappointing sales figures due to lower prices.

Persons: Fluor, Sunnova, Moderna, StreetAccount, — CNBC's Brian Evans, Lisa Han Organizations: Intel, UBS, Apple, Sunnova Energy, Truist Securities, Moderna, pharma, Bank of America, Novartis —, Swiss drugmaker, Sandoz, SIX Swiss Exchange, Maine Foods, Revenue Locations: United States, Israel, Swiss, Cal

☆ FDA authorizes updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.
▼ + stars: | 2023-10-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

"In the coming days, individuals in the U.S. can go to major pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine." Last month, the FDA and CDC greenlit XBB.1.5 shots from Pfizer and Moderna for all Americans ages six months and older. The end of that declaration means all three manufacturers will sell their updated shots directly to health-care providers and vie for commercial market share. That includes the Biden administration's Bridge Access Program, which will provide Covid vaccines at no cost to underinsured and uninsured people. It's unclear how many Americans will actually roll up their sleeves and take the new vaccines from Novavax, Pfizer and Moderna.

Persons: Novavax, John Jacobs, fends, Demetre Daskalakis, Biden, it's, Eris, Megan Wallace Organizations: Drug Administration, Pfizer, Moderna, Centers for Disease Control, Covid, FDA, CDC, EG, Biden Locations: U.S, Novavax

A vial labelled "Novavax COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Maryland-based company, whose COVID vaccine is its lone marketed product, has adopted cost-cutting measures and is counting on commercial sales of its updated shot to help it stay afloat. The CDC's Advisory Committee on Immunization Practices (ACIP) will not meet again to discuss the Novavax shot, a spokesperson said. Novavax's original COVID shot received U.S. authorization in July 2022, long after Pfizer and Moderna vaccines were in use. All three of the updated shots target the XBB.1.5 variant of the coronavirus.

Persons: Dado Ruvic, BioNTech, COVID, John Jacobs, Jacobs, Sriparna Roy, Bill Berkrot Organizations: REUTERS, U.S . Food, Drug Administration, U.S . Centers for Disease Control, Prevention, Pfizer Inc, Moderna, FDA, Pfizer, Moderna's, Thomson Locations: U.S, Maryland, Bengaluru

☆ Goldman analysts say these stocks have the most upside — including 3 expected to double
▼ + stars: | 2023-10-03 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Kostin outlined several stocks that Goldman thinks have the most upside based on the firm's target price. Etsy could gain more than 70% over the next 12 months, according to Goldman's price target on the e-commerce platform. Moderna has the largest potential upside from Goldman's target price at 175.9%. Another stock that is expected to more than double is FMC , a chemical manufacturing company with a focus on agriculture. Shares are off about 48% in 2023, but Goldman Sachs sees 101.6% upside for the stock.

Persons: Goldman Sachs, David Kostin, Kostin, Goldman, Etsy, SolarEdge, FactSet, — CNBC's Michael Bloom Organizations: Barclays, Moderna, FMC, Revenue Locations: Europe

Search resuls for: "modernă"

25 mentions found